The diagnostic value of serum exosomal SNORD116 and SNORA21 for NSCLC patients
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03606-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Lin Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Intravenous Admixture Services, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, China. Hauptthemen laut MEDLINE: Exosomes, Carcinoma, Non-Small-Cell Lung, Biomarkers, Tumor, Lung Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, National Natural Science Foundation of China, Nursery Project of the Affiliated Taian City Central Hospital of Qingdao University.
Abstract (Originalsprache)
PURPOSE: Non-small cell lung cancer (NSCLC) is a widespread and serious global malignancy. This study aimed to examine the clinical relevance of serum exosomal SNORD116 and SNORA21 as novel diagnostic biomarkers for NSCLC. METHODS: Serum exosomes from 226 healthy controls and 305 NSCLC patients were isolated by ultracentrifugation. Characterization of exosomes was conducted by qNano, transmission electron microscopy (TEM) and Western immunoblotting. RT-PCR revealed snoRNAs that were differentially expressed. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic performance. RESULTS: In NSCLC patients, the levels of serum exosomal SNORD116 and SNORA21 were significantly reduced compared to those in healthy controls (P < 0.0001 for both). ROC curves showed AUC values of 0.738 and 0.761. By combining SNORD116 and SNORA21 with traditional blood biomarkers CYFRA21-1 and carcinoembryonic antigen (CEA), the AUC increased to 0.917. Moreover, these two exosomal snoRNAs distinguished between patients with metastatic NSCLC (n = 132) and those with non-metastatic NSCLC (n = 173) significantly (P < 0.0001 for both). The ROC curves gave AUC values of 0.743 and 0.694, respectively. The combined analysis raised the AUC to 0.751. The diagnostic power of these two exosomal snoRNAs combined with CYFRA21-1 and CEA increased to 0.784. CONCLUSION: This study demonstrated that serum exosomal SNORD116 and SNORA21 can be used as potential promising non-invasive diagnostic biomarkers for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Intravenous Admixture Services, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, China.
- Department of Clinical Laboratory, The Affiliated Taian City Central Hospital of Qingdao University, Taian, 271000, China.
- Shandong Provincial Key Medical and Health Laboratory of Anti-drug Resistant drug research, Taian City Central Hospital, Taian, 271000, China.
- Medical Research & Laboratory Diagnostic Center, Shandong Academy of Medical Sciences, Central Hospital Affiliated to Shandong First Medical University, 105 Jiefang Road, Jinan, 250013, China.
- Medical Research & Laboratory Diagnostic Center, Shandong Academy of Medical Sciences, Central Hospital Affiliated to Shandong First Medical University, 105 Jiefang Road, Jinan, 250013, China. fxdnash@163.com.
Förderung
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
- Nursery Project of the Affiliated Taian City Central Hospital of Qingdao University
Zitieren
APA
Li, L., Zhang, Z., Xu, W., Wang, J., & Feng, X. (2024). The diagnostic value of serum exosomal SNORD116 and SNORA21 for NSCLC patients. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03606-1
Vancouver
Li L, Zhang Z, Xu W, Wang J, Feng X. The diagnostic value of serum exosomal SNORD116 and SNORA21 for NSCLC patients. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03606-1
BibTeX
@article{Li2024,
author = {Li, Lin and Zhang, Zhijun and Xu, Wei and Wang, Jun and Feng, Xiaodong},
title = {The diagnostic value of serum exosomal SNORD116 and SNORA21 for NSCLC patients},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03606-1}
}
EUVIMED